Natus Medical Incorporated NTUS
Set alert
As of Apr 24, 3:47 PM ET
52-week range unavailable
- Open
- 32.90
- Prev close
- 32.96
- Mkt cap
- 1.14B
- Vol
- 132.70K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 32.84
- High
- 33.07
- Forward P/E
- 20.99
- Beta
- 0.23
- Short ratio
- 4.11
- Inst. own
- 95.20%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 4, 2022
- 50-d avg
- 32.61
- 200-d avg
- 27.38
- 1y target
- 0.00
2Y chart
Events in this range
- Nov 4, 2021Earnings: —; estimate 0.3; surprise —%
- Feb 24, 2022Earnings: —; estimate 0.44; surprise —%
- May 5, 2022Earnings: —; estimate 0.26; surprise —%
Signals (25)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Jul 19, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 14, 2022 | 4 years ago |
| SMA: Bullish | Jun 30, 2022 | 4 years ago |
| SMA: Bearish | Jun 29, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 27, 2022 | 4 years ago |
| SMA: Bullish | Jun 24, 2022 | 4 years ago |
| SMA: Bearish | Jun 22, 2022 | 4 years ago |
| SMA: Bullish | Jun 21, 2022 | 4 years ago |
| SMA: Bearish | Jun 16, 2022 | 4 years ago |
| RSI: Oversold | Jun 16, 2022 | 4 years ago |
| MACD: Sell Signal | May 5, 2022 | 4 years ago |
| MACD: Buy Signal | Apr 18, 2022 | 4 years ago |
| RSI: Overbought | Apr 18, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 5, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 31, 2022 | 4 years ago |
| SMA: Bullish | Mar 24, 2022 | 4 years ago |
| SMA: Bearish | Mar 23, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 10, 2022 | 4 years ago |
| RSI: Overbought | Feb 25, 2022 | 4 years ago |
| SMA: Bullish | Feb 22, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 10, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 26, 2022 | 4 years ago |
| SMA: Bearish | Jan 24, 2022 | 4 years ago |
| SMA: Bullish | Jan 21, 2022 | 4 years ago |
| RSI: Oversold | Dec 1, 2021 | 4 years ago |
Key statistics
- Market cap
- 1.14B
- Enterprise value
- 1.05B
- Trailing P/E
- 86.74
- Forward P/E
- 20.99
- PEG ratio
- 1.04
- Price / sales
- 2.38
- Price / book
- 2.62
- EPS (TTM)
- 0.38
- Beta
- 0.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 2.65%
- Revenue (TTM)
- 478.30M
- Revenue growth
- 4.20%
- Free cash flow
- 52.88M
- Total cash
- 84.28M
- Total debt
- 10.24M
- Return on equity
- 3.02%
- Shares outstanding
- 34.58M
- Short % of float
- 6.11%
- 50-day average
- 32.61
- 200-day average
- 27.38
Analyst view
Consensus: hold
Next earnings
Aug 4, 2022
Expected Aug 4, 2022. Consensus EPS estimate 0.32.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 4, 2022 | Jun 1, 2022 | 0.32 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | 0.26 | — | — | — |
| Feb 24, 2022 | Dec 1, 2021 | 0.44 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | 0.30 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | 0.29 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | 0.16 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2, 2017 | Raymond James | down | Outperform | Market Perform |
| Oct 4, 2016 | Benchmark | init | — | Buy |
| Sep 13, 2016 | Raymond James | up | Market Perform | Outperform |
| Apr 5, 2016 | Roth Capital | main | — | Buy |
| Oct 7, 2014 | William Blair | down | Market Perform | Outperform |
| May 6, 2013 | CJS Securities | init | — | Market Perform |
About Natus Medical Incorporated
Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers essential products used in the everyday operation of neonatal intensive care unit (NICU); balance assessment systems to evaluate patients with balance disorders; and NICVIEW, a live streaming video for families with babies in the NICU. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was formerly known as ALGOTEK Instruments, Inc. and changed its name to Natus Medical Incorporated in September 1988. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Middleton, Wisconsin.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- natus.com
News
- INVESTIGATION NOTICE: Halper Sadeh LLP Investigates USWS, GDST, NTUS, CMAX
- Earnings Scheduled For May 5, 2022
- Has Natus Medical (NTUS) Outpaced Other Medical Stocks This Year?
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ACC, NTUS, FSI, VWTR
- Here is why Natus Medical is up 25%
- 68 Biggest Movers From Yesterday
- Why Natus Medical Stock Surged Today
- 34 Stocks Moving In Monday's Mid-Day Session
- Natus Medical Soars. It's Being Taken Private by ArchiMed for $1.2 Billion.
- Neurodiagnostic Focused Natus Medical Goes Private In $1.2B Deal
Your note
Sign in to keep a note on NTUS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHUNG DONG CHUNE CHRISTOPHER | Officer | Sale | Dec 8, 2021 | 39,926 |
| DASKAL ILAN | Director | Stock Award(Grant) | Jun 14, 2022 | 18,937 |
| DAVIES BENJAMIN DREW | Chief Financial Officer | Stock Award(Grant) | Jul 20, 2022 | 0 |
| GUERIN ERIC | Director | Stock Award(Grant) | Jun 14, 2022 | 10,114 |
| HEINE LISA WIPPERMAN | Director | Stock Award(Grant) | Jun 14, 2022 | 26,287 |
| LEVINE JOSHUA H | Director | Stock Award(Grant) | Jun 14, 2022 | 37,387 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 18.82% | 6,506,467 | 214.45M | Mar 30, 2022 |
| Vanguard Group, Inc. (The) | 8.85% | 3,058,873 | 100.82M | Mar 30, 2022 |
| Victory Capital Management Inc. | 7.63% | 2,637,254 | 86.92M | Mar 30, 2022 |
| Allspring Global Investments Holdings, LLC | 6.06% | 2,096,944 | 69.12M | Mar 30, 2022 |
| Dimensional Fund Advisors LP | 4.04% | 1,398,692 | 46.10M | Mar 30, 2022 |
| State Street Corporation | 3.89% | 1,345,374 | 44.34M | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 7.08% | 2,447,194 | 80.66M | Jun 29, 2022 |
| Victory Portfolios-Sycamore Small Company Opportunity Fund | 3.94% | 1,361,000 | 44.86M | Apr 29, 2022 |
| Janus Henderson Small Cap Value Fund | 3.23% | 1,115,726 | 36.77M | Mar 30, 2022 |
| Vanguard Total Stock Market Index Fund | 2.82% | 975,293 | 32.15M | Mar 30, 2022 |
| Allspring Special Small Cap Value Fund | 2.81% | 972,567 | 32.06M | May 30, 2022 |
| iShares Russell 2000 ETF | 2.26% | 780,122 | 25.71M | Jun 29, 2022 |